Some recent studies have confirmed that a high Ki67 proliferation index and c-MYC/BCL-2 co-expression in DLBCL were independently associated with poor clinical outcomes [2,12,13]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.